Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
dtQkUHw8FYRFXh0c
